
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

**October 18, 2016
(Date of earliest event reported)**

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of Incorporation)

1-11353
(Commission
File Number)

13-3757370
(I.R.S. Employer
Identification No.)

**358 South Main Street,
Burlington, North Carolina**
(Address of principal executive offices)

27215
(Zip Code)

336-229-1127
(Registrant's telephone number
including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 Regulation FD Disclosure

On October 18, 2016, Sequenom, Inc., a wholly owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced final results for the tender offers for the 5.00% Convertible Senior Notes Due 2017 (CUSIP No. 817337 AB4) and 5.00% Convertible Exchange Senior Notes Due 2018 (CUSIP No. 817337 AC2) issued by Sequenom.

A copy of the press release announcing the final tender offer results is being furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits**Exhibits**

99.1 Press Release issued by Sequenom, dated October 18, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings
Registrant

By: /s/ F. SAMUEL EBERTS III
F. Samuel Eberts III
Chief Legal Officer and Secretary

October 18, 2016



Laboratory Corporation of America® Holdings
358 South Main Street
Burlington, NC 27215
Telephone: (336) 584-5171
www.labcorp.com

FOR IMMEDIATE RELEASE

Contact: Paul Surdez (investors) – 336-436-5076
Investor@labcorp.com
Pattie Kushner (media) – 336-436-8263
Media@labcorp.com

LabCorp Subsidiary Sequenom, Inc. Announces Expiration of and Final Tender Results for Tender Offers for 5% Convertible Senior Notes Due 2017 and 5% Convertible Senior Exchange Notes Due 2018

BURLINGTON, N.C. and SAN DIEGO, CA, October 18, 2016 — Sequenom, Inc. (“Sequenom”), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), announced the final results, as of 5:00 p.m., New York City time, on Monday, October 17, 2016 (the “Expiration Date”), of the cash tender offers (the “Tender Offers”) for any and all of the outstanding 5% Convertible Senior Notes Due 2017 (CUSIP No. 817337 AB4, the “2017 Notes”) and 5% Convertible Senior Exchange Notes Due 2018 (CUSIP No. 817337 AC2, the “2018 Notes” and, together with the 2017 Notes, the “Notes”) issued by Sequenom.

The depository for the tender offers has advised Sequenom that, as of the Expiration Date, (i) a total of \$44,871,000 aggregate principal amount of the outstanding 2017 Notes, representing approximately 99.713% of the outstanding 2017 Notes, were validly tendered (and not validly withdrawn), and (ii) a total of \$85,000,000 aggregate principal amount of the outstanding 2018 Notes, representing 100.00% of the outstanding 2018 Notes, were validly tendered (and not validly withdrawn) in the Tender Offers.

Sequenom has accepted for purchase all 2017 Notes and 2018 Notes properly tendered and not validly withdrawn in the Tender Offers. Holders whose 2017 Notes were validly tendered on or before 5:00 p.m., New York City time, on September 29, 2016 (the “Early Tender and Consent Payment Deadline”), and not withdrawn, will receive, in respect of each \$1,000 principal amount of 2017 Notes, the “2017 Total Consideration” of \$1,037.50 plus Accrued Interest (such price being rounded to the nearest \$0.01 per \$1,000 principal outstanding amount of Notes) on October 20, 2016 (the “Settlement Date”). Holders whose 2018 Notes were validly tendered on or before the Early Tender and Consent Payment Deadline, and not withdrawn, will receive, in respect of each \$1,000 principal amount of 2018 Notes, the “2018 Total Consideration” of \$1,046.25 plus Accrued Interest (such price being rounded to the nearest \$0.01 per \$1,000 principal outstanding amount of Notes) on the Settlement Date. Holders whose 2017 Notes were validly tendered after the Early Tender and Consent Payment Deadline but on or prior to the Expiration Date, and not withdrawn, will receive, in respect of each \$1,000 principal amount of 2017 Notes tendered, the “Purchase Price” of \$1,000.00, plus accrued interest to but excluding the Settlement Date. No tenders of Notes will be valid if submitted after the Expiration Date.

Barclays acted as the dealer manager and solicitation agent for the Tender Offers.

About LabCorp®

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is the world's leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of \$8.5 billion in 2015, LabCorp's 50,000 employees serve clients in 60 countries. To learn more about LabCorp visit www.labcorp.com and to learn more about Covance Drug Development visit www.covance.com.

This press release contains forward-looking statements including with respect to the payment of consideration for Sequenom Notes tendered in the Tender Offers. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by these forward-looking statements. Risks and uncertainties include, among others factors detailed in LabCorp's and Sequenom's filings with the SEC including LabCorp's Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent SEC filings, and Sequenom's Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent SEC filings. LabCorp undertakes no obligation to update these statements as a result of new events, circumstances or otherwise.